Compare BridgeBio Pharma Inc (BBIO) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.53. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | HYG | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | Fixed Income |
52-Week High | $90.17 | $81.32 |
52-Week Low | $47.29 | $78.72 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
HYG trades at $79.61, up 0.19% on the day, with a bullish technical signal driven by oscillators despite bearish moving averages. Recent dividends include $0.41 paid in June 2026. News highlights bond market volatility amid oil price swings and inflation data anticipation, with HYG noted for its high-yield corporate bond exposure and liquidity as the largest junk bond ETF.
Outlook hinges on interest rate trends and economic stability, offering income through dividends but facing risks from rising yields and credit spreads. Investors should weigh HYG's role in diversified portfolios against potential downside from macroeconomic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
